A Case Report on the Development of Ulcerative Colitis During Osimertinib Therapy for Epidermal Growth Factor Receptor Mutation‐Positive Non‐Small‐Cell Lung Cancer
ABSTRACT Osimertinib, a standard treatment for epidermal growth factor receptor (EGFR)‐positive non‐small‐cell lung cancer, commonly causes manageable diarrhoea. We report osimertinib‐induced refractory diarrhoea diagnosed as ulcerative colitis, remitting with mesalazine. A 69‐year‐old woman with ad...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Respirology Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rcr2.70272 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ABSTRACT Osimertinib, a standard treatment for epidermal growth factor receptor (EGFR)‐positive non‐small‐cell lung cancer, commonly causes manageable diarrhoea. We report osimertinib‐induced refractory diarrhoea diagnosed as ulcerative colitis, remitting with mesalazine. A 69‐year‐old woman with advanced‐stage EGFR mutation‐positive lung adenocarcinoma developed persistent diarrhoea 3 weeks after starting osimertinib, complicated by anorexia, hypotension, anaemia and renal failure requiring hospitalisation. While anaemia and renal failure improved after osimertinib cessation, diarrhoea persisted. A colonoscopy revealed ulcerative colitis, confirmed by neutrophil and lymphocyte infiltration in the intestinal mucosa, glandular deformation and decreased goblet cells. This case demonstrates that osimertinib‐induced ulcerative colitis was successfully treated with mesalazine. |
|---|---|
| ISSN: | 2051-3380 |